RT Journal Article SR Electronic T1 COVID-19 primary series and booster vaccination and immune imprinting JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.10.31.22281756 DO 10.1101/2022.10.31.22281756 A1 Chemaitelly, Hiam A1 Ayoub, Houssein H. A1 Tang, Patrick A1 Coyle, Peter A1 Yassine, Hadi M. A1 Al Thani, Asmaa A. A1 Al-Khatib, Hebah A. A1 Hasan, Mohammad R. A1 Al-Kanaani, Zaina A1 Al-Kuwari, Einas A1 Jeremijenko, Andrew A1 Kaleeckal, Anvar Hassan A1 Latif, Ali Nizar A1 Shaik, Riyazuddin Mohammad A1 Abdul-Rahim, Hanan F. A1 Nasrallah, Gheyath K. A1 Al-Kuwari, Mohamed Ghaith A1 Butt, Adeel A. A1 Al-Romaihi, Hamad Eid A1 Al-Thani, Mohamed H. A1 Al-Khal, Abdullatif A1 Bertollini, Roberto A1 Abu-Raddad, Laith J. YR 2022 UL http://medrxiv.org/content/early/2022/11/01/2022.10.31.22281756.abstract AB Background Epidemiological evidence for immune imprinting was investigated in immune histories related to vaccination in Qatar from onset of the omicron wave, on December 19, 2021, through September 15, 2022.Methods Matched, retrospective, cohort studies were conducted to investigate differences in incidence of SARS-CoV-2 reinfection in the national cohort of persons who had a primary omicron infection, but different vaccination histories. History of primary-series (two-dose) vaccination was compared to that of no vaccination, history of booster (three-dose) vaccination was compared to that of two-dose vaccination, and history of booster vaccination was compared to that of no vaccination. Associations were estimated using Cox proportional-hazards regression models.Results The adjusted hazard ratio comparing incidence of reinfection in the two-dose cohort to that in the unvaccinated cohort was 0.43 (95% CI: 0.38-0.48). The adjusted hazard ratio comparing incidence of reinfection in the three-dose cohort to that in the two-dose cohort was 1.38 (95% CI: 1.16-1.65). The adjusted hazard ratio comparing incidence of reinfection in the three-dose cohort to that in the unvaccinated cohort was 0.53 (95% CI: 0.44-0.63). All adjusted hazard ratios appeared stable over 6 months of follow-up. Divergence in cumulative incidence curves in all comparisons increased markedly when incidence was dominated by BA.4/BA.5 and BA.2.75*. No reinfection in any cohort progressed to severe, critical, or fatal COVID-19.Conclusions History of primary-series vaccination enhanced immune protection against omicron reinfection, but history of booster vaccination compromised protection against omicron reinfection. These findings do not undermine the short-term public health utility of booster vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for institutional salary support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for institutional salary support provided by the Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine. The authors are also grateful for the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review boards at Hamad Medical Corporation and Weill Cornell Medicine in Qatar approved this retrospective study with a waiver of informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.